Format

Send to

Choose Destination
Clin Cancer Res. 2019 Aug 5. doi: 10.1158/1078-0432.CCR-18-0856. [Epub ahead of print]

Immune Activation in Mismatch Repair-Deficient Carcinogenesis: More Than Just Mutational Rate.

Author information

1
Hematology and Oncology Fellowship Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
2
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
3
MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, Texas.
4
Department of Medicine, Weill-Cornell Medical College, Cornell University, New York, New York.
5
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas. EVilar@mdanderson.org.

Abstract

Mismatch repair (MMR)-deficient colorectal cancers (dMMR colorectal cancer) are characterized by the expression of highly immunogenic neoantigen peptides, which stimulate lymphocytic infiltration as well as upregulation of inflammatory cytokines. These features are key to understanding why immunotherapy (specifically PD-1 and/or CTLA-4 checkpoint blockade) has proved to be highly effective for the treatment of patients with advanced dMMR colorectal cancer. Importantly, preclinical studies also suggest that this correlation between potent tumor neoantigens and the immune microenvironment is present in early (premalignant) stages of dMMR colorectal tumorigenesis as well, even in the absence of a high somatic mutation burden. Here, we discuss recent efforts to characterize how neoantigens and the tumor immune microenvironment coevolve throughout the dMMR adenoma-to-carcinoma pathway. We further highlight how this preclinical evidence forms the rational basis for developing novel immunotherapy-based colorectal cancer prevention strategies for patients with Lynch syndrome.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center